JP2012509348A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012509348A5 JP2012509348A5 JP2011537624A JP2011537624A JP2012509348A5 JP 2012509348 A5 JP2012509348 A5 JP 2012509348A5 JP 2011537624 A JP2011537624 A JP 2011537624A JP 2011537624 A JP2011537624 A JP 2011537624A JP 2012509348 A5 JP2012509348 A5 JP 2012509348A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pharmaceutically acceptable
- acceptable salt
- composition
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08169462 | 2008-11-19 | ||
| EP08169462.2 | 2008-11-19 | ||
| PCT/US2009/065188 WO2010059853A1 (en) | 2008-11-19 | 2009-11-19 | Tgr5 modulators and method of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014088019A Division JP2014159456A (ja) | 2008-11-19 | 2014-04-22 | Ｔｇｒ５モジュレーターおよびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012509348A JP2012509348A (ja) | 2012-04-19 |
| JP2012509348A5 true JP2012509348A5 (enExample) | 2012-12-13 |
| JP5535233B2 JP5535233B2 (ja) | 2014-07-02 |
Family
ID=41668454
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011537624A Expired - Fee Related JP5535233B2 (ja) | 2008-11-19 | 2009-11-19 | Ｔｇｒ５モジュレーターおよびその使用方法 |
| JP2014088019A Withdrawn JP2014159456A (ja) | 2008-11-19 | 2014-04-22 | Ｔｇｒ５モジュレーターおよびその使用方法 |
| JP2015160141A Pending JP2015232020A (ja) | 2008-11-19 | 2015-08-14 | Ｔｇｒ５モジュレーターおよびその使用方法 |
| JP2017083045A Withdrawn JP2017132803A (ja) | 2008-11-19 | 2017-04-19 | Ｔｇｒ５モジュレーターおよびその使用方法 |
| JP2018059922A Withdrawn JP2018100304A (ja) | 2008-11-19 | 2018-03-27 | Ｔｇｒ５モジュレーターおよびその使用方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014088019A Withdrawn JP2014159456A (ja) | 2008-11-19 | 2014-04-22 | Ｔｇｒ５モジュレーターおよびその使用方法 |
| JP2015160141A Pending JP2015232020A (ja) | 2008-11-19 | 2015-08-14 | Ｔｇｒ５モジュレーターおよびその使用方法 |
| JP2017083045A Withdrawn JP2017132803A (ja) | 2008-11-19 | 2017-04-19 | Ｔｇｒ５モジュレーターおよびその使用方法 |
| JP2018059922A Withdrawn JP2018100304A (ja) | 2008-11-19 | 2018-03-27 | Ｔｇｒ５モジュレーターおよびその使用方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US8114862B2 (enExample) |
| EP (2) | EP2698375B1 (enExample) |
| JP (5) | JP5535233B2 (enExample) |
| KR (2) | KR101667436B1 (enExample) |
| CN (2) | CN104370990A (enExample) |
| AU (1) | AU2009316566B9 (enExample) |
| BR (1) | BRPI0921983B8 (enExample) |
| CA (1) | CA2744189C (enExample) |
| DK (2) | DK2376519T3 (enExample) |
| EA (2) | EA020140B1 (enExample) |
| ES (2) | ES2458168T3 (enExample) |
| HK (1) | HK1205132A1 (enExample) |
| HU (1) | HUE039171T2 (enExample) |
| IL (3) | IL212969A (enExample) |
| LT (1) | LT2698375T (enExample) |
| MX (1) | MX2011005295A (enExample) |
| NO (1) | NO2698375T3 (enExample) |
| PL (2) | PL2376519T3 (enExample) |
| PT (2) | PT2376519E (enExample) |
| SG (1) | SG10201400162QA (enExample) |
| SI (1) | SI2698375T1 (enExample) |
| WO (1) | WO2010059853A1 (enExample) |
| ZA (1) | ZA201104077B (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1392714B1 (en) | 2001-03-12 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Steroids as agonists for fxr |
| US10987362B2 (en) | 2004-03-12 | 2021-04-27 | Intercept Pharmaceuticals, Inc. | Treatment of fibrosis using FXR ligands |
| ES2533993T3 (es) | 2004-03-12 | 2015-04-16 | Intercept Pharmaceuticals, Inc. | Tratamiento de fibrosis usando ligandos de FXR |
| ITMI20050912A1 (it) | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
| CN101679476B (zh) | 2007-01-19 | 2014-05-07 | 英特塞普特医药品公司 | 23取代的胆汁酸作为tgr5调节剂及其使用方法 |
| EP2324046B1 (en) | 2008-07-30 | 2014-09-03 | Intercept Pharmaceuticals, Inc. | Tgr5 modulators and methods of use thereof |
| CN104370990A (zh) * | 2008-11-19 | 2015-02-25 | 英特塞普特医药品公司 | G蛋白偶联受体5(tgr5)调节剂及其使用方法 |
| US9339480B2 (en) | 2008-11-26 | 2016-05-17 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of obesity and diabetes |
| CN102316889B (zh) | 2008-11-26 | 2014-11-26 | 萨蒂奥根制药公司 | 组合物及使用方法 |
| US20110294767A1 (en) | 2010-05-26 | 2011-12-01 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| ES2633766T3 (es) | 2011-10-28 | 2017-09-25 | Lumena Pharmaceuticals Llc | Inhibidores de reciclaje de ácido biliar para el tratamiento de enfermedades de hígado colestático pediátrico |
| AU2012328453B2 (en) | 2011-10-28 | 2017-05-04 | Shire Human Genetic Therapies, Inc. | Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease |
| US9982008B2 (en) | 2012-06-19 | 2018-05-29 | Intercept Pharmaceuticals, Inc. | Preparation and uses of obeticholic acid |
| NZ734451A (en) | 2012-06-19 | 2018-12-21 | Intercept Pharmaceuticals Inc | Preparation, uses and solid forms of obeticholic acid |
| US9726663B2 (en) | 2012-10-09 | 2017-08-08 | The Procter & Gamble Company | Method of identifying or evaluating synergistic combinations of actives and compositions containing the same |
| CN104704362B (zh) | 2012-10-09 | 2018-08-28 | 宝洁公司 | 鉴定或评估有益活性物质的方法以及包含其的组合物 |
| EP3004132A4 (en) | 2013-06-06 | 2017-01-18 | Yissum, Research Development Company of the Hebrew | Bile acid-basic amino acid conjugates and uses thereof |
| AU2014278833A1 (en) * | 2013-06-13 | 2016-01-07 | Fast Forward Pharmaceuticals B.V. | CD40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an TGR5-receptor agonist, an FXR agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis. |
| EP3985118A1 (en) | 2013-11-22 | 2022-04-20 | MiNA Therapeutics Limited | C/ebp alpha short activating rna compositions and methods of use |
| MX388957B (es) * | 2014-05-29 | 2025-03-20 | Bar Pharmaceuticals S R L | Derivados del colano para uso en el tratamiento y/o prevencion de enfermedades en las que intervienen el fxr y el tgr5/gpbar1 |
| WO2016054208A1 (en) * | 2014-10-03 | 2016-04-07 | Mayo Foundation For Medical Education And Research | Targeting tgr5 to treat disease |
| CA2966885A1 (en) * | 2014-11-06 | 2016-05-12 | Enanta Pharmaceuticals, Inc. | Bile acid analogs an fxr/tgr5 agonists and methods of use thereof |
| MX381239B (es) | 2014-11-19 | 2025-03-12 | Nzp Uk Ltd | Esteroides de 6.alfa.-alquil-6,7-diona como intermedios para la producción de moduladores esteroideos del receptor x farnesoide (fxr). |
| JP6724004B2 (ja) | 2014-11-19 | 2020-07-15 | エヌゼットピー ユーケー リミテッド | ステロイドＦＸＲモジュレーター製造のための中間体としての５β−６−アルキル−７−ヒドロキシ−３−オンステロイド |
| EA033427B1 (ru) | 2014-11-19 | 2019-10-31 | Nzp Uk Ltd | 6-алкил-7-гидрокси-4-ен-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr |
| EA034739B1 (ru) | 2014-11-19 | 2020-03-16 | ЭнЗедПи ЮКей ЛИМИТЕД | 6-альфа-алкил-3,7-дионовые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr |
| CN105985396A (zh) * | 2015-02-16 | 2016-10-05 | 苏州泽璟生物制药有限公司 | 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 |
| EP3290429A1 (en) * | 2015-04-28 | 2018-03-07 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Cholic acid derivative, and preparation method and medical use thereof |
| US10800807B2 (en) * | 2015-06-19 | 2020-10-13 | Intercept Pharmaceuticals, Inc. | TGR5 modulators and methods of use thereof |
| CN107771180B (zh) * | 2015-06-19 | 2021-03-23 | 英特塞普特医药品公司 | Tgr5调节剂及其使用方法 |
| JP2018528230A (ja) * | 2015-09-24 | 2018-09-27 | インターセプト ファーマシューティカルズ， インコーポレイテッド | 胆汁酸誘導体の調製のための方法および中間体 |
| TW201718621A (zh) * | 2015-10-07 | 2017-06-01 | 英特賽普醫藥品公司 | 法尼醇x受體調節劑 |
| CN106008639B (zh) * | 2016-03-11 | 2019-01-08 | 深圳市塔吉瑞生物医药有限公司 | 用于预防或治疗fxr-介导疾病的胆烷酸化合物 |
| CA3020698A1 (en) | 2016-04-13 | 2017-10-19 | Intercept Pharmaceuticals, Inc. | Methods of treating or preventing hepatocellular carcinoma |
| GB201608777D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Compounds |
| CN108990420B (zh) | 2016-05-29 | 2022-06-24 | 深圳市绘云生物科技有限公司 | 肝病相关生物标志物和其使用方法 |
| WO2018005794A2 (en) * | 2016-07-01 | 2018-01-04 | Venenum Biodesign Llc | Novel non-systemic tgr5 agonists |
| WO2018222701A1 (en) * | 2017-05-30 | 2018-12-06 | Intercept Pharmaceuticals, Inc. | Treatment of renal diseases with a bile acid derivative |
| CN109021056B (zh) * | 2017-06-09 | 2021-03-09 | 博瑞生物医药（苏州）股份有限公司 | 法尼酯x受体激动剂 |
| JP2020528892A (ja) | 2017-07-24 | 2020-10-01 | インターセプト ファーマシューティカルズ， インコーポレイテッド | 同位体標識化胆汁酸誘導体 |
| AU2018330494A1 (en) | 2017-09-08 | 2020-03-26 | Mina Therapeutics Limited | HNF4a saRNA compositions and methods of use |
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
| EP3920937A4 (en) * | 2019-02-04 | 2022-11-02 | Intercept Pharmaceuticals, Inc. | TREATMENT AND PREVENTION OF INFLAMATORY BOWEL DISEASES WITH A BILE ACID DERIVATIVE |
| CN116925168A (zh) * | 2019-08-23 | 2023-10-24 | 深圳云合医药科技合伙企业(有限合伙) | 胆汁酸衍生物及其组合物和应用 |
| JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | Ｇｐｒ１１９アゴニスト |
| TW202140440A (zh) | 2020-02-28 | 2021-11-01 | 美商克力歐普股份有限公司 | Gpr40激動劑 |
| AU2021275038A1 (en) | 2020-05-19 | 2022-12-22 | Kallyope, Inc. | AMPK activators |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
| KR102693566B1 (ko) * | 2020-07-03 | 2024-08-08 | 주식회사 큐라클 | 지방간 질환의 예방 또는 치료를 위한 약학적 조성물 |
| CN113774142A (zh) * | 2021-10-11 | 2021-12-10 | 北京化工大学 | Tgr5在制备治疗肠癌药物及诊断性试剂盒中的应用 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3366932D1 (en) | 1982-07-29 | 1986-11-20 | Lehner Ag | New derivatives of biliary acids, process for the production thereof and pharmaceutical compositions containing the same |
| IT1206112B (it) | 1983-04-29 | 1989-04-14 | Lehner Ag | Nuovi derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche. |
| IT1212835B (it) | 1983-08-18 | 1989-11-30 | Lehner Ag | Derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche. |
| US4892868A (en) * | 1984-08-17 | 1990-01-09 | Gipharmex, S.P.A. | Derivatives of biliary acids, process for the production thereof and corresponding pharmaceutical compositions |
| IT1196377B (it) | 1984-12-21 | 1988-11-16 | Lehner Ag | Derivati di acidi biliari,procedimento per la loro preparazione e relative composizioni farmaceutiche |
| IT1223313B (it) * | 1987-10-20 | 1990-09-19 | Gipharmex Spa | Derivati di acidi biliari loro preparazione e composizioni farmaceutiche che li contengono |
| IT1229570B (it) | 1989-04-17 | 1991-09-04 | Giuliani Spa | Derivati fluorurati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono. |
| US5175320A (en) * | 1989-04-17 | 1992-12-29 | Giuliani S.P.A. | Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them |
| ATE121080T1 (de) * | 1989-12-13 | 1995-04-15 | Mitsubishi Chem Corp | Pyrazolylacrylsäure-derivate, verwendbar als systemische fungiziden in pflanzen- und materialschutz. |
| WO1997028149A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| GB9604242D0 (en) | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| GB9606805D0 (en) | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
| US5689791A (en) | 1996-07-01 | 1997-11-18 | Xerox Corporation | Electrically conductive fibers |
| EP0921798A1 (en) | 1996-07-12 | 1999-06-16 | Smithkline Beecham Plc | Novel treatment of leptine resistance |
| US6008237A (en) * | 1997-12-19 | 1999-12-28 | Merck & Co., Inc. | Arylthiazolidinedione derivatives |
| US6200995B1 (en) | 1998-01-29 | 2001-03-13 | Tularik Inc. | PPAR-γ modulators |
| WO2000025134A1 (en) | 1998-10-23 | 2000-05-04 | Glaxo Group Limited | Assays for ligands for nuclear receptors |
| JP2002532729A (ja) | 1998-12-23 | 2002-10-02 | グラクソ グループ リミテッド | 核内受容体のリガンドのアッセイ |
| WO2000040965A1 (en) | 1999-01-07 | 2000-07-13 | Tularik, Inc. | Fxr receptor-mediated modulation of cholesterol metabolism |
| AU780658B2 (en) | 1999-03-26 | 2005-04-07 | City Of Hope | Method of affecting cholesterol catabolism using nuclear bile acid receptor |
| US20020132223A1 (en) | 1999-03-26 | 2002-09-19 | City Of Hope | Methods for modulating activity of the FXR nuclear receptor |
| EP1473042B1 (en) | 1999-03-26 | 2006-06-21 | City of Hope | Screening for FXR receptor modulators |
| EP1185277B1 (en) | 1999-06-11 | 2005-10-26 | Allergan, Inc. | Use of FXR synthetic ligands for the treatment of diseseas linked to cholesterol imbalance and colon cancer |
| US6906057B1 (en) * | 1999-06-11 | 2005-06-14 | Allergan, Inc. | Methods for modulating FXR receptor activity |
| US6559188B1 (en) * | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
| WO2001030343A1 (en) | 1999-10-22 | 2001-05-03 | Merck & Co., Inc. | Pharmaceuticals for treating obesity |
| EP1273659A4 (en) | 2000-04-12 | 2004-04-21 | Takeda Chemical Industries Ltd | G-PROTEIN COUPLED RECEPTOR PROTEIN AND ITS DNA |
| US6627636B2 (en) * | 2000-06-15 | 2003-09-30 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| US6777446B2 (en) * | 2000-09-05 | 2004-08-17 | Tularik, Inc. | FXR modulators |
| US20020119958A1 (en) | 2001-02-13 | 2002-08-29 | Shinichiro Tojo | Therapeutic agent for hyperlipidemia |
| EP1392714B1 (en) * | 2001-03-12 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Steroids as agonists for fxr |
| US7354726B2 (en) | 2001-04-12 | 2008-04-08 | Takeda Pharmaceutical Company Limited | Screening method |
| EP1285914B1 (en) | 2001-08-13 | 2007-12-19 | PheneX Pharmaceuticals AG | Nr1h4 nuclear receptor binding compounds |
| WO2003016280A1 (en) | 2001-08-13 | 2003-02-27 | Lion Bioscience Ag | Nr1h4 nuclear receptor binding compounds |
| WO2003015777A1 (en) | 2001-08-13 | 2003-02-27 | Lion Bioscience Ag | Nr1h4 nuclear receptor binding compounds |
| US20030144360A1 (en) | 2001-11-19 | 2003-07-31 | Allergan Sales, Inc. | Composition and method for modulating BAR/FXR receptor activity |
| US20050107475A1 (en) | 2002-03-21 | 2005-05-19 | Jones Stacey A. | Methods of using farnesoid x receptor (frx) agonists |
| EP1494533A2 (en) | 2002-04-12 | 2005-01-12 | The University of Chicago | Farnesoid x-activated receptor agonists |
| US6987121B2 (en) | 2002-04-25 | 2006-01-17 | Smithkline Beecham Corporation | Compositions and methods for hepatoprotection and treatment of cholestasis |
| WO2004000752A1 (ja) | 2002-06-19 | 2003-12-31 | Availvs Corporation | 人造石壁材 |
| ITMI20021532A1 (it) | 2002-07-12 | 2004-01-12 | Roberto Pellicciari | Composti chimici |
| AU2003290700A1 (en) | 2002-11-22 | 2004-06-18 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
| EP1591120A4 (en) | 2003-01-28 | 2009-06-10 | Takeda Chemical Industries Ltd | RECEPTOR AGONISTS |
| WO2005032549A1 (en) | 2003-09-26 | 2005-04-14 | Smithkline Beecham Corporation | Compositions and methods for treatment of fibrosis |
| EP1568706A1 (en) | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Novel steroid agonist for FXR |
| ES2533993T3 (es) | 2004-03-12 | 2015-04-16 | Intercept Pharmaceuticals, Inc. | Tratamiento de fibrosis usando ligandos de FXR |
| ITMI20050912A1 (it) | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
| SI2040713T1 (sl) | 2006-06-27 | 2014-11-28 | Intercept Pharmaceuticals, Inc. | Derivati žolčne kisline kot FXR ligandi za preprečevanje ali zdravljenje bolezni ali stanj, posredovanih s FXR |
| EP1947108A1 (en) | 2007-01-19 | 2008-07-23 | Intercept Pharmaceuticals, Inc. | TGR5 modulators and methods of use thereof |
| CN101679476B (zh) * | 2007-01-19 | 2014-05-07 | 英特塞普特医药品公司 | 23取代的胆汁酸作为tgr5调节剂及其使用方法 |
| CN104370990A (zh) * | 2008-11-19 | 2015-02-25 | 英特塞普特医药品公司 | G蛋白偶联受体5(tgr5)调节剂及其使用方法 |
-
2009
- 2009-11-19 CN CN201410532890.0A patent/CN104370990A/zh active Pending
- 2009-11-19 PL PL09760057T patent/PL2376519T3/pl unknown
- 2009-11-19 PT PT97600571T patent/PT2376519E/pt unknown
- 2009-11-19 US US12/622,123 patent/US8114862B2/en active Active
- 2009-11-19 JP JP2011537624A patent/JP5535233B2/ja not_active Expired - Fee Related
- 2009-11-19 CA CA2744189A patent/CA2744189C/en active Active
- 2009-11-19 LT LTEP13192394.8T patent/LT2698375T/lt unknown
- 2009-11-19 AU AU2009316566A patent/AU2009316566B9/en active Active
- 2009-11-19 WO PCT/US2009/065188 patent/WO2010059853A1/en not_active Ceased
- 2009-11-19 BR BRPI0921983A patent/BRPI0921983B8/pt not_active IP Right Cessation
- 2009-11-19 EP EP13192394.8A patent/EP2698375B1/en active Active
- 2009-11-19 SI SI200931820T patent/SI2698375T1/sl unknown
- 2009-11-19 NO NO13192394A patent/NO2698375T3/no unknown
- 2009-11-19 ES ES09760057.1T patent/ES2458168T3/es active Active
- 2009-11-19 ES ES13192394T patent/ES2663948T3/es active Active
- 2009-11-19 SG SG10201400162QA patent/SG10201400162QA/en unknown
- 2009-11-19 KR KR1020117014037A patent/KR101667436B1/ko not_active Expired - Fee Related
- 2009-11-19 EA EA201170714A patent/EA020140B1/ru unknown
- 2009-11-19 CN CN200980154713.0A patent/CN102325784B/zh active Active
- 2009-11-19 HU HUE13192394A patent/HUE039171T2/hu unknown
- 2009-11-19 DK DK09760057.1T patent/DK2376519T3/da active
- 2009-11-19 KR KR1020167028159A patent/KR101789960B1/ko not_active Expired - Fee Related
- 2009-11-19 EP EP09760057.1A patent/EP2376519B1/en active Active
- 2009-11-19 MX MX2011005295A patent/MX2011005295A/es active IP Right Grant
- 2009-11-19 DK DK13192394.8T patent/DK2698375T3/en active
- 2009-11-19 PL PL13192394T patent/PL2698375T3/pl unknown
- 2009-11-19 EA EA201400258A patent/EA030681B1/ru not_active IP Right Cessation
- 2009-11-19 PT PT131923948T patent/PT2698375T/pt unknown
-
2011
- 2011-05-18 IL IL212969A patent/IL212969A/en active IP Right Grant
- 2011-06-01 ZA ZA2011/04077A patent/ZA201104077B/en unknown
- 2011-12-07 US US13/313,689 patent/US8445472B2/en not_active Expired - Fee Related
-
2013
- 2013-04-26 US US13/871,492 patent/US9650409B2/en not_active Expired - Fee Related
-
2014
- 2014-04-22 JP JP2014088019A patent/JP2014159456A/ja not_active Withdrawn
-
2015
- 2015-06-10 HK HK15105499.8A patent/HK1205132A1/xx unknown
- 2015-08-14 JP JP2015160141A patent/JP2015232020A/ja active Pending
-
2016
- 2016-03-29 IL IL244812A patent/IL244812B/en active IP Right Grant
-
2017
- 2017-04-07 US US15/482,107 patent/US20180016295A1/en not_active Abandoned
- 2017-04-19 JP JP2017083045A patent/JP2017132803A/ja not_active Withdrawn
-
2018
- 2018-03-27 JP JP2018059922A patent/JP2018100304A/ja not_active Withdrawn
-
2019
- 2019-02-12 IL IL264796A patent/IL264796B/en active IP Right Grant
-
2020
- 2020-11-09 US US17/092,612 patent/US20210269473A1/en not_active Abandoned